EU approves Sanofi’s Sarclisa subcutaneous via on-body injector for multiple myeloma
Share
Listen to the news
EU approves Sanofi’s Sarclisa subcutaneous via on-body injector for multiple myeloma
  • EU regulators cleared Sanofi’s subcutaneous Sarclisa for multiple myeloma across all indications already authorized for the IV version.
  • Decision enables administration via an on-body injector or manual injection, supporting home or outpatient use.
  • Approval was backed by phase 3 IRAKLIA data showing non-inferior efficacy versus IV dosing in relapsed or refractory disease.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606080100PRIMZONEFULLFEED1001186336) on June 08, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending